Krishnan Nandabalan Net Worth & Insider Trades
Krishnan Nandabalan - Director, Bioxcel Therapeutics, Inc
What is Krishnan Nandabalan's Net Worth?
The current estimated net worth of Bioxcel Therapeutics, Inc's Director, Krishnan Nandabalan, is estimated to be about $287.9M . Krishnan Nandabalan owns about 8,546,750 units of Bioxcel Therapeutics, Inc common stock. In the last 5 years at Bioxcel Therapeutics, Inc, Krishnan Nandabalan has sold an estimated value of $35.56M worth.
What is Krishnan Nandabalan's Past Insider Trading?
Krishnan Nandabalan's largest purchase order was 60,000 units , worth over $24.6K on January 6, 2023. Krishnan Nandabalan's largest sale order was 473,250 units , worth over $14.59M on June 29, 2021. In total, Krishnan Nandabalan has made about 7 transactions over 5 years of their time at Bioxcel Therapeutics, Inc. Krishnan Nandabalan usually trades in November, with the busiest year in 2020 and 2021.
Krishnan Nandabalan
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What is Krishnan Nandabalan's' Mailing Address?
- Mailing address is 228 Village Pond Road Guilford CT 06437 CT
Bioxcel Therapeutics, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|
| Vimal Mehta, Ph.D. | 2020 | $890,000 | - | $8,122,500 | $556,250 | $7,800 | $9,576,550 |
| Vimal Mehta, Ph.D. | 2019 | $459,000 | - | $1,269,131 | $233,000 | $7,800 | $1,968,931 |
| William P. Kane, Jr. | 2020 | $245,455 | - | $4,185,500 | $138,699 | - | $4,569,654 |
| Reina Benabou, M.D., Ph.D. | 2020 | $197,443 | - | $2,462,400 | $76,341 | - | $2,736,184 |
| No matching records found | |||||||
Source: https://www.sec.gov/Archives/edgar/data/1720893/000110465921055605/tm212482-3_def14a.htm
What are Bioxcel Therapeutics, Inc's Past Insider Trades?
Bioxcel Therapeutics, Inc's most recent insider trade came on March 16, 2023 by Richard Steinhart who sold 2,084 units worth $40.64K . In the last 5 years, insiders at Bioxcel Therapeutics, Inc have sold an estimated value of $137.31M and bought an estimated value of $20.05M worth of shares. Insider trading is most common in March, with the busiest year in 2021. The most active traders at the company are Vimal Mehta, CEO and President, Frank Yocca, Chief Scientific Officer, and Peter Mueller, Director .
BioXcel Therapeutics, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||